Please login to the form below
Shock as NICE turns down Biogen’s SMA therapy
UK’s cost effectiveness watchdog says the drug’s long-term benefits are unclear
FDA gives breakthrough status to Xolair for food allergies
Food allergies could open up big new market for biologic
Confidence in UK’s post-Brexit healthcare sector on the wane
Only 37% of healthcare workers agree that the UK would be an attractive destination after EU departure
Promising more appraisal capacity, NICE revives industry fee idea
Rising workload and shrinking budget making charges inevitable
Can a post-Brexit UK stay aligned with Europe on clinical research?
There's still no guarantee the UK can keep in step with EU
FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo
Becomes the first drug approved to treat Sézary syndrome
Pharma survey: No Brexit is the best option
But many believe a 'no deal' Brexit most likely outcome
UK unveils plans for bigger medicines price squeeze
Company payments to government would rise steeply to 2021
As ‘No Deal’ fears grow, pharma can’t rely on transition period
UK could still remain part of EMA 'club' until 2020 - but time is running out
Moving times
Continuity and stability are vital when it comes to the EMA's relocation when it leaves London
-
SMC gives green light for Amgen’s KyprolisThe committee also gives verdict on three other products
-
Facing the new wave of biosimilarsDon’t drown out the patient voice, says advocacy group
-
Ionis and Roche gain PRIME status for Huntingdon’s disease candidateMore good news for Ionis after first drug approval
-
Daiichi gets breakthrough status for pre-NDA leukaemia drugQuizartinib could have an advantage over rival drug Rydapt
-
EMA cuts back as Brexit staff losses top expectationsRegulator says it faces loss of 30% of staff
-
Sanofi latest to reveal Brexit stockpiling of drugsCompany says UK job losses inevitable in event of hard or no deal Brexit
-
First migraine prevention drug to hit European marketEuropean Commission green lights Novartis’ Aimovig
-
Alnylam’s amyloidosis drug heads latest crop of CHMP approvalsThree new biosimilars also gets the green light
-
Bluebird’s first gene therapy gets European fast trackFor once, Europe set for approval and launch ahead of US
Latest regulatory appointments
-
Professor Carole Longson moves from NICE to the ABPIShe joins the UK pharma body as its chief scientific officer
-
MedTech Europe appoints new board of directors
Chair of the board Michelle Brennan is among those newly elected
-
Greg Perry joins IFPMA as assistant director generalWill move to the global industry body from the Medicines Patent Pool
-
AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance
He joins the biopharma from Tang Capital Management
-
IFPMA names new communications director
Helen Gallagher joins the association from Ferring Pharmaceuticals
Featured jobs
-
Medical Director
-
Excellent benefits
- Freelance Senior Account Manager – healthcare advertising
-
Employment Type:. Healthcare Advertising Jobs. Salary:. 250 to 320 per day
- Account Director or Senior Account Director
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
-
Market Access Consultant - Cheshire
-
Negotiable
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior Account Manager / Account Director
-
Great salary and bebefits
-
Senior Medical Writer
-
Great salary and bebefits
-
Scientific Director
-
Great salary and bebefits
- Multi-Channel Account Managers - Road / Homebased – Full or Part...
-
starting from £32, 500
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
Subscribe to our email news alerts
- How can pharma engage with key stakeholders on NHS service transformation?
- The race for an HIV ‘cure’
- Medopad: the up and coming unicorn transforming remote patient monitoring
- Novo spends $800m to buy biotech and 'glucose responsive insulin' tech
- Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more
- Armoured CAR ‘could overwhelm solid tumour resistance’
PMHub
BASTARD . LONDON
BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...
Latest intelligence
- How can pharma engage with key stakeholders on NHS service transformation?
- Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
- The race for an HIV ‘cure’
- Supercharging therapies as pharma and patients work together...
- Medopad: the up and coming unicorn transforming remote patient monitoring
- Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....
Quick links
Infographics
